CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

Climb Bio reports Phase I results for CLYM116 in IgA nephropathy

Phase 1positiveCLYM116Positive
AI Analysis

Summary

Climb Bio reported positive initial Phase I results for CLYM116, an APRIL monoclonal antibody candidate being developed to treat IgA nephropathy.

Clinical Trial Data

Phase

Phase I

Importance:5/10
Sentiment:
0.70
Phase ICLYM116IgA nephropathymonoclonal antibodyAPRIL
Related Companies

Read the original article

Published by Clinical Trials Arena on September 4, 2026 10:01 AM

Read Original